Alzheimer’s Disease & Related Dementias Family Support Program | NYU Langone Health
NYU Langone’s Alzheimer’s Disease and Related Dementias Family Support Program provides free services to family caregivers in New York City.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol: ATRI-001
Discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research.Aim 1. Longitudinal changes in cognition and associated biomarkersDetermine and define those measures of cognition and function, including composite measures, and those biomarker measures, which capture longitudinal change with the highest statistical power to detect treatment effects in clinical trials.Longitudinal change of cerebral tau measured with 18F-AV-1451 PET (AV-1451) will be correlated/compared with other measures.Aim 2. Prediction of cognitive declineDetermine which clinical, cognitive, and biomarker measures that best predict decline of cognition in CN, MCI, and AD participants. In addition, determine which biomarker changes correlate with cognitive decline, with focus on AV-1451 PET.Aim 3. ValidationValidate biomarker measures obtained at Baseline and longitudinally by correlating results with “gold standard” clinical measurements and pathology.Aim 4. Clinical trial designDetermine the optimum outcome measures with attention to cognitive decline and AV-1451 PET, predictors of cognitive decline, and inclusion/exclusion criteria for clinical trials of cognitively normal participants (for secondary preclinical AD trials), MCI patients (for prodromal AD trials) and participants with early dementia due to AD.Aim 5. DiscoveryTo determine the effects of other known disease proteins found in AD brains and genes, as well as newly discovered genes, proteins, and analytes that provide useful information concerning the pathogenesis/diagnosis of AD.Protocol Clarifications:only those with the capacity to consent will be considered for retention in the ADNI study.
Alzheimer’s Disease Support | NYU Langone Health
NYU Langone specialists offer compassionate, supportive care for people with Alzheimer’s disease, their families, and caregivers.
Ambulatory Care Expansion | NYU Langone Health
NYU Langone’s reach is increasingly extending further into the surrounding neighborhood and region.
Ambulatory Care Pharmacy | NYU Langone Health
The pharmacists at NYU Langone’s Ambulatory Care Pharmacy make getting a prescription filled quick, easy, and convenient.
Amyloidosis Program | NYU Langone Health
Experts in the Amyloidosis Program at NYU Langone’s Perlmutter Cancer Center specialize in the diagnosis and treatment of amyloidosis.
Amyotrophic Lateral Sclerosis | NYU Langone Health
Doctors at NYU Langone provide an accurate diagnosis and ongoing support to people with ALS and their families.
An Adaptive Phase 2a/2b Randomized Double-Blind Placebo-Controlled Study of LY3871801 in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis
This study is being done to see how safe an investigational drug is and how well it will work to help people with moderately to severely active rheumatoid arthritis (RA).
An Evaluation of Home Urinalysis Testing for Systemic Lupus Erythematosus (SLE) Patients at Elevated Risk for Developing Lupus Nephritis: A Pilot Stage and Randomized Controlled Study
Pilot Study: Feasibility, acceptability, and adaptation. We will produce a teaching video for home-based proteinuria testing that will instruct patients on how to collect a sample and evaluate the home colorimetric dipsticks (only protein, Siemens Albutrix).The urinalysis video planned, which will simply instruct the patients how to line up the dipsticks with the single protein color chart and match the color most closely corresponding to their urine. A scoring system will be explained, such that the color matching will be assigned as follows: negative = 1, trace = 2, +300 (.300g/l) = 3, 1.000g/l = 4, 3.000g/l = 5, 10.000g/l = 6.Following informed consent at their clinic visit, 18 participating patients will view the educational video, with available subtitles in all three languages (i.e., English, Spanish and Mandarin. The patient will have sufficient dipsticks to test the first morning void once weekly for a year (with weekly reminders via a text protocol) unless earlier intervention is required. For reporting the weekly score, the patient will be instructed to respond to the text they receive on the morning of the weekly dipstick check and enter the number corresponding to the color matching the dipstick, and indicate “period” if menstruating. If the score provided by the patient is 3 or greater for two consecutive weeks, the texting program will be programmed to alert the coordinator to call the patient and ask the patient come to the local laboratory for a formal UPCR. A UPCR of 0.5 or greater would trigger an immediate SOC visit with Drs. Buyon, Saxena, Belmont, or Izmirly. We will be using the HIPAA-compliant texting platform, SlickText, for patient communication. Participants will be able to send STOP message to opt out, and the only information included is their phone number. Additionally, they will be able to send TEAM message to receive a call from the coordinator if they encounter any difficulties. Each participant will receive texts in their preferred language. Feasibility for Stage 1 will be assessed quantitatively by the number of patients approached for the evaluation versus number willing to participate, with 70% participating as considered feasible. Acceptability will be determined if =80% of participants respond that they are at least moderately satisfied, using a brief Client Satisfaction Questionnaire. Data on adherence and implementation feasibility will be captured via SlickText (number of weeks returning a dipstick value divided by overall weeks, accommodating menstruation when urinalysis may not be completed, although patients will be instructed to collect the urine and record their period). Adherence of 75% will be considered successful. Further, we will aim to clinically validate the scores reported by patients who have a scheduled standard-of-care visit preferably on the same day as the weekly morning dipstick scoring is done; we will attempt to assure that patient score readings of 1 or 2 correspond to UPCR < 0.3. If we find errors, we will coach the patient and check their supply of dipsticks for deterioration. At the middle and end of the first year of the protocol, we will conduct debriefing interviews to evaluate the personal experiences and satisfaction with the intervention and modify the protocol accordingly. Clinical Trial To Follow: Implement a larger randomized controlled trial (RCT) among all eligible in the NYU Lupus Cohort (160 participating patients). Patients will be enrolled and randomized (1:1) to home testing intervention in addition to standard of care or standard of care only. Patients who have a scheduled standard-of-care visit preferably on the same day as the weekly morning dipstick scoring is done; we will attempt to assure that patient score readings of 1 or 2 correspond to UPCR < 0.3. The primary outcome will be that has a clinical indication for a kidney biopsy (UPCR 0.5 regardless of either de novo or relapsed disease), whether or not the patient actually undergoes the procedure.
An observational multi-center study to validate outcome measures for future clinical trials of Multiple System Atrophy (MSA)
The purpose of this research study is to develop and validate new methods to measure if a potential drug being tested in future clinical trials of patients with multiple system atrophy (MSA) is effective. These methods include a scale or questionnaire (“clinical outcome assessment” or COA), brain neuroimaging (magnetic resonance imaging or MRI) and biochemical biomarkers (blood or cerebrospinal fluid (CSF) samples).